Collaboration will engage leading transplant clinician-scientists to study antibody-mediated rejection (AMR) and microvascular inflammation (MVI) using cellular-resolution profiling BRISBANE, Calif.-- ...
Collaboration will engage leading transplant clinician-scientists to study antibody-mediated rejection (AMR) and microvascular inflammation (MVI) using cellular-resolution profiling BRISBANE, Calif., ...
Precision medicine company CareDx and 10x Genomics have partnered to launch ImmuneScape, a multiomics program to improve the understanding of transplant organ rejection and variability in patient ...
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value ...
For families navigating rare diseases, the promise of AI-guided genomics is especially tangible. Many of these conditions are linked to genetic mutations that can be scattered across the genome, and ...